Results Presented at the International Conference on Opioids and Published in a Peer-Reviewed Journal Demonstrate that Proove Technology Can Help Primary Care Physicians on the Frontline of the Opioid Abuse Epidemic
IRVINE, Calif., June 15, 2017 /PRNewswire/ — Proove® Biosciences, Inc. announces a new peer-reviewed study demonstrating the accuracy of Proove Opioid Risk® to help primary care physicians predict patients at-risk for opioid abuse. This study, entitled, “Validation Study of a Predictive Algorithm to Evaluate Opioid Use Disorder in a Primary Care Setting” has been accepted for publication by the journal Health Services Research & Managerial Epidemiology. This study data was presented as part of a presentation by Proove collaborators entitled, “Utilizing Precision Medicine Technologies to Avoid and Treat Prescription Opioid Abuse.” Panelists included Lynn Webster, MD, FACPM, FASAM; Ramsay Farah, MD, MPH, FAAP, FACPM, FASAM, CPE, CMRO; and Katrina Lewis, MD, BSc.
Researchers teamed with Proove® scientists to conduct a multi-center study in 27 primary care clinics involving 1,689 patients. This study demonstrates that Proove Opioid Risk® is a stable predictor of Opioid Use Disorder (OUD) in a primary care setting with 83.2% accuracy. Compared to questionnaires like the Opioid Risk Tool (ORT) or Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) which struggle to accurately identify patients at low risk, Proove Opioid Risk® has a sensitivity ranging from 91.8% to 100% in its low risk range of scores.
Dr. Ashley Brenton, Director of R&D at Proove and lead author states, “The CDC Guidelines targeting primary care physicians are not enough, as the CDC readily admits synthetic opioid deaths have only increased 72% since their publication. Clearly, physicians need better tools. This study validates that Proove Opioid Risk® is a stable predictor of opioid abuse in primary care, and confirms other published studies showing this profile’s high accuracy.”
Proove CEO Brian Meshkin explains, “This study adds to the mounting evidence that precision medicine can accurately identify at-risk patients and guide treatment to reduce pain. It’s a false choice to suggest that we must only choose between restricting opioids to reduce abuse and thereby hurting chronic pain patients, or allowing opioids liberally prescribed to control pain and thus expand opioid abuse. We can reduce pain and opioid abuse at the same time.”